U.S. Physical Therapy (NYSE:USPH) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report issued on Saturday, January 6th. The brokerage presently has a $82.00 target price on the stock. Zacks Investment Research‘s price objective points to a potential upside of 7.97% from the company’s previous close.
According to Zacks, “U.S. Physical Therapy, Inc. is the largest publicly-traded, pure-play operator of outpatient physical and occupational therapy clinics, with over 500 Clinics in 42 States. The clinics provide pre- and post-operative care for a variety of orthopedic-related disorders and sports-related injuries, rehabilitation of injured workers and preventative care. USPh also manages several physical therapy facilities for third parties, including physician groups. Each of USPh’s clinics are directed by a licensed physical therapist that drive patient volume via local physicians, former patients and other referral sources. Marketing representatives are used to further augment sales. Historically, USPh has grown its business through de novo development; approximately two-thirds of USPh clinics were originally start-ups. Strategic acquisitions, which accelerate the Company’s growth, are structured like the de novo partnerships, with significant ownership retained by founders. “
Other research analysts have also recently issued research reports about the company. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $72.00 price target on shares of U.S. Physical Therapy in a report on Tuesday, September 26th. BidaskClub raised U.S. Physical Therapy from a “strong sell” rating to a “sell” rating in a report on Thursday, September 28th. Barrington Research downgraded shares of U.S. Physical Therapy from an “outperform” rating to a “market perform” rating in a research note on Friday, November 3rd. Finally, Sidoti raised shares of U.S. Physical Therapy from a “neutral” rating to a “buy” rating and boosted their target price for the company from $62.00 to $74.00 in a research note on Friday, September 8th. Three analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $73.80.
Shares of U.S. Physical Therapy (NYSE:USPH) traded down $0.55 during trading hours on Friday, reaching $75.95. The company had a trading volume of 37,656 shares, compared to its average volume of 40,574. U.S. Physical Therapy has a 1 year low of $56.50 and a 1 year high of $78.00. The company has a market capitalization of $966.86, a PE ratio of 45.75, a price-to-earnings-growth ratio of 2.84 and a beta of 1.09. The company has a debt-to-equity ratio of 0.30, a quick ratio of 2.04 and a current ratio of 2.04.
U.S. Physical Therapy (NYSE:USPH) last announced its earnings results on Thursday, November 2nd. The company reported $0.48 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.52 by ($0.04). U.S. Physical Therapy had a return on equity of 13.37% and a net margin of 5.29%. The firm had revenue of $103.03 million for the quarter, compared to the consensus estimate of $102.69 million. equities analysts predict that U.S. Physical Therapy will post 2.07 earnings per share for the current fiscal year.
In related news, CFO Lawrance W. Mcafee sold 800 shares of the company’s stock in a transaction on Friday, November 3rd. The shares were sold at an average price of $69.21, for a total value of $55,368.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director Mark J. Brookner sold 2,625 shares of the company’s stock in a transaction on Wednesday, December 27th. The stock was sold at an average price of $71.23, for a total transaction of $186,978.75. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 31,875 shares of company stock worth $2,173,623. 3.10% of the stock is currently owned by corporate insiders.
Large investors have recently modified their holdings of the stock. Wells Fargo & Company MN boosted its holdings in U.S. Physical Therapy by 2.1% in the second quarter. Wells Fargo & Company MN now owns 45,372 shares of the company’s stock worth $2,740,000 after purchasing an additional 914 shares in the last quarter. Rhumbline Advisers boosted its holdings in U.S. Physical Therapy by 15.8% in the third quarter. Rhumbline Advisers now owns 40,729 shares of the company’s stock worth $2,503,000 after purchasing an additional 5,570 shares in the last quarter. BNP Paribas Arbitrage SA boosted its holdings in U.S. Physical Therapy by 57.1% in the third quarter. BNP Paribas Arbitrage SA now owns 6,452 shares of the company’s stock worth $396,000 after purchasing an additional 2,346 shares in the last quarter. Aberdeen Asset Management PLC UK boosted its holdings in U.S. Physical Therapy by 13.4% in the second quarter. Aberdeen Asset Management PLC UK now owns 705,007 shares of the company’s stock worth $42,582,000 after purchasing an additional 83,253 shares in the last quarter. Finally, King Luther Capital Management Corp boosted its holdings in U.S. Physical Therapy by 61.3% in the third quarter. King Luther Capital Management Corp now owns 57,695 shares of the company’s stock worth $3,545,000 after purchasing an additional 21,935 shares in the last quarter. Hedge funds and other institutional investors own 94.13% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “Zacks Investment Research Upgrades U.S. Physical Therapy (USPH) to Buy” was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this news story on another domain, it was illegally copied and republished in violation of U.S. & international copyright and trademark legislation. The original version of this news story can be read at https://www.dispatchtribunal.com/2018/01/31/u-s-physical-therapy-usph-upgraded-at-zacks-investment-research.html.
About U.S. Physical Therapy
U.S. Physical Therapy, Inc, through its subsidiaries, operates outpatient physical therapy clinics that provide pre-and post-operative care, and treatment for orthopedic-related disorders, sports-related injuries, preventative care, rehabilitation of injured workers and neurological-related injuries.
Get a free copy of the Zacks research report on U.S. Physical Therapy (USPH)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for U.S. Physical Therapy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for U.S. Physical Therapy and related companies with MarketBeat.com's FREE daily email newsletter.